Related references
Note: Only part of the references are listed.Transforming growth factor-beta in tissue fibrosis
Nikolaos G. Frangogiannis
JOURNAL OF EXPERIMENTAL MEDICINE (2020)
TGF-β orchestrates fibrogenic and developmental EMTs via the RAS effector RREB1
Jie Su et al.
NATURE (2020)
Management of myelofibrosis after ruxolitinib failure
Claire N. Harrison et al.
ANNALS OF HEMATOLOGY (2020)
CDK6 is an essential direct target of NUP98 fusion proteins in acute myeloid leukemia
Johannes Schmoellerl et al.
BLOOD (2020)
Fibrosis: from mechanisms to medicines
Neil C. Henderson et al.
NATURE (2020)
Transforming Growth Factor-β Signaling in Immunity and Cancer
Eduard Batlle et al.
IMMUNITY (2019)
Reversine exhibits antineoplastic activity in JAK2V617F-positive myeloproliferative neoplasms
Keli Lima et al.
SCIENTIFIC REPORTS (2019)
CDK6 coordinates JAK2V617F mutant MPN via NF-κB and apoptotic networks
Iris Z. Uras et al.
BLOOD (2019)
Dual Targeting of Oncogenic Activation and Inflammatory Signaling Increases Therapeutic Efficacy in Myeloproliferative Neoplasms
Maria Kleppe et al.
CANCER CELL (2018)
The functional diversity of Aurora kinases: a comprehensive review
Estelle Willems et al.
CELL DIVISION (2018)
Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms
William Vainchenker et al.
BLOOD (2017)
A comprehensive review on Aurora kinase: Small molecule inhibitors and clinical trial studies
Ankit C. Borisa et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2017)
Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study
Claire N. Harrison et al.
LANCET HAEMATOLOGY (2017)
Hmga2 promotes the development of myelofibrosis in Jak2V617F knockin mice by enhancing TGF-β1 and Cxcl12 pathways
Avik Dutta et al.
BLOOD (2017)
Efficacy of ALK5 inhibition in myelofibrosis
Lanzhu Yue et al.
JCI INSIGHT (2017)
CDK6-a review of the past and a glimpse into the future: from cell-cycle control to transcriptional regulation
A-S Tigan et al.
ONCOGENE (2016)
Targeting megakaryocytic-induced fibrosis in myeloproliferative neoplasms by AURKA inhibition
Qiang Jeremy Wen et al.
NATURE MEDICINE (2015)
The history and future of targeting cyclin-dependent kinases in cancer therapy
Uzma Asghar et al.
NATURE REVIEWS DRUG DISCOVERY (2015)
Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer
Nicholas C. Turner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
CDK6 as a key regulator of hematopoietic and leukemic stem cell activation
Ruth Scheicher et al.
BLOOD (2015)
Dysregulation of the MIRLET7/HMGA2 axis with methylation of the CDKN2A promoter in myeloproliferative neoplasms
Kayo Harada-Shirado et al.
BRITISH JOURNAL OF HAEMATOLOGY (2015)
Requirement for CDK6 in MLL-rearranged acute myeloid leukemia
Theresa Placke et al.
BLOOD (2014)
Loss of wild-type Jak2 allele enhances myeloid cell expansion and accelerates myelofibrosis in Jak2V617F knock-in mice
H. Akada et al.
LEUKEMIA (2014)
Definition and management of ruxolitinib treatment failure in myelofibrosis
A. Pardanani et al.
BLOOD CANCER JOURNAL (2014)
Characterization of the TGF-β1 signaling abnormalities in the Gata1low mouse model of myelofibrosis
Maria Zingariello et al.
BLOOD (2013)
A comprehensive review and analysis of the effect of ruxolitinib therapy on the survival of patients with myelofibrosis
John Mascarenhas et al.
BLOOD (2013)
The Lin28b-let-7-Hmga2 axis determines the higher self-renewal potential of fetal haematopoietic stem cells
Michael R. Copley et al.
NATURE CELL BIOLOGY (2013)
Somatic CALR Mutations in Myeloproliferative Neoplasms with Nonmutated JAK2
J. Nangalia et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Somatic Mutations of Calreticulin in Myeloproliferative Neoplasms
Thorsten Klampfl et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis
Srdan Verstovsek et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis
Claire Harrison et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
DIPSS Plus: A Refined Dynamic International Prognostic Scoring System for Primary Myelofibrosis That Incorporates Prognostic Information From Karyotype, Platelet Count, and Transfusion Status
Naseema Gangat et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Efficacy of the JAK2 inhibitor INCB16562 in a murine model of MPLW515L-induced thrombocytosis and myelofibrosis
Priya Koppikar et al.
BLOOD (2010)
Conditional expression of heterozygous or homozygous Jak2V617F from its endogenous promoter induces a polycythemia vera-like disease
Hajime Akada et al.
BLOOD (2010)
A Requirement for Cyclin-Dependent Kinase 6 in Thymocyte Development and Tumorigenesis
Miaofen G. Hu et al.
CANCER RESEARCH (2009)
Cell cycle, CDKs and cancer: a changing paradigm
Marcos Malumbres et al.
NATURE REVIEWS CANCER (2009)
Molecular profiling of CD34(+) cells in idiopathic myelofibrosis identifies a set of disease-associated genes and reveals the clinical significance of Wilms' tumor gene 1 (WT1)
Paola Guglielmelli et al.
STEM CELLS (2007)
MPL515 mutations in myeloproliferative and other myeloid disorders:: a study of 1182 patients
Animesh D. Pardanani et al.
BLOOD (2006)
MPLW515L is anovel somatic activating mutation in myelofibrosis with myeloid metaplasia
Yana Pikman et al.
PLOS MEDICINE (2006)
Pathogenesis of myelofibrosis with myeloid metaplasia
A Tefferi
JOURNAL OF CLINICAL ONCOLOGY (2005)
Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles
A Subramanian et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Mammalian cells cycle without the D-type cyclin-elependent kinases Cdk4 and Cdk6
M Malumbres et al.
CELL (2004)
Prominent role of TGF-β1 in thrombopoietin-induced myelofibrosis in mice
H Chagraoui et al.
BLOOD (2002)
Share Paper
